Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02923713
Other study ID # CR016768
Secondary ID TMC114-TiDP29-C2
Status Active, not recruiting
Phase Phase 2
First received September 30, 2016
Last updated September 30, 2016
Start date October 2010
Est. completion date June 2017

Study information

Verified date September 2016
Source Janssen Sciences Ireland UC
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationIreland: Irish Agriculture and Food Development AuthorityFrance: Agence Nationale de Sécurité du Médicament et des produits de santéSpain: Agencia Española de Medicamentos y Productos SanitariosArgentina: Administración Nacional de Medicamentos, Alimentos y Tecnología MédicaSouth Africa: Medicines Control CouncilIndia: Central Drugs Standard Control OrganizationUkraine: Ministry of HealthGreat Britain: Medicines and Healthcare Products Regulatory AgencyBrazil: National Health Surveillance Agency (ANVISA)Ukraine: Ministry of Health - Ukraine
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to continue to provide Darunavir (DRV) to pediatric patients who previously received DRV in any of three pediatric clinical studies sponsored by Tibotec Pharmaceuticals and continue to benefit from using it, in countries where DRV is not yet commercially available for the pediatric patient, is not reimbursed or cannot be accessed through another source (like access program or government program).


Description:

This study has the aim to continue the provision of DRV and rtv to pediatric patients that continue to benefit from treatment with it after participation in any of three ongoing pediatric studies sponsored by Tibotec Pharmaceuticals. In addition, information on the safety of DRV and rtv in combination with other antiretroviral therapies will be assessed. At the baseline visit, inclusion and exclusion criteria will be checked to confirm eligibility. Once eligible, patients will continue treatment either on the once daily dose regimen (when coming from the TMC114-TiDP29-C230 study) or a twice daily regimen (when coming from the TMC114-C212 or TMC114-TiDP29-C228 studies). Assessments and visit frequency will take place as per local standard of care but are desirable every 3 months. The interval between two visits should not exceed 6 months. Pregnancy testing for girls having had their first menses is foreseen. In addition, it is desirable that testing includes efficacy assessments (immunology and plasma viral load) and laboratory safety assessments (hematology, biochemistry including pancreatic amylase (if available) or lipase and lipid analysis). Serious Adverse Events and certain selected Adverse Events will be collected. Treatment will be continued until one of the following criteria is met (whichever occurs first): Virologic failure, treatment limiting toxicity, loss to follow-up, withdrawal of consent or assent by the patient or withdrawal of consent by the caregiver, pregnancy, termination of the trial by the sponsor, when Darunavir becomes commercially available, is reimbursed or can be accessed through another source (as there are access program or government program) in the region the patient is living in. The sponsor advises participating centers to plan the study visits every 3 months but frequency will depend on local practice and standard of care. The sponsor has also foreseen in the study protocol a guidance on specific safety assessments to be performed as well as detailed instructions on how to deal with specific toxicities and undesirable effects. However local practice will prevail and the assessments performed may vary depending on the region the patient is participating in. Intake of study medication will happen once daily or twice daily, depending on what the patient took in the original pediatric trial. For the twice daily regimen, the regimen may be adjusted as the patient gains weight. The adult dosage regimen of 600/100 mg DRV/rtv may be administered as of 40 kg of body weight. Depending on the history of the patient, following dosages may be administered: DRV oral suspension (100mg DRV/ml), DRV tablets 75 mg, 150 mg, 600 mg, all for twice daily intake. DRV 400 mg for the once daily 800 mg intake (2 tablets per intake). DRV intake will be combined with rtv in oral suspension (80 mg rtv/ml), capsule or tablet (both 100 mg).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 46
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender Both
Age group 3 Years to 99 Years
Eligibility Inclusion Criteria:

- Patient has completed the TMC114-C212, TMC114-TiDP29-C228 or TMC114-TiDP29-C230 study and continues to benefit from DRV

- DRV is not commercially available, not reimbursed or cannot be accessed through another way

- signed informed consent by parents/caregivers or assent by the patient is available prior to inclusion

Exclusion Criteria:

- Any condition or active clinically significant disease (such as pancreas problems or cardiac problems) endangering the patient safety while being enrolled in the study

- Previously demonstrated clinically significant allergy or hypersensitivity to the study medication

- Pregnancy or breastfeeding female patients

- Specific criteria will be applicable for girls having had their first menses and for girls and boys having reached the age of sexual activity

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Darunavir
600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
Ritonavir
Liquid formulation, 80 mg/ml, taken in combination with Darunavir
Ritonavir
100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
Darunavir
Oral suspension 100 mg/ml, 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
Ritonavir
100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
Darunavir
375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
Darunavir
450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
Darunavir
400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
Ritonavir
100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
Darunavir
375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
Ritonavir
Liquid formulation, 80 mg/ml, taken in combination with Darunavir
Darunavir
450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
Darunavir
600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
Ritonavir
100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
Ritonavir
Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Janssen Sciences Ireland UC

Countries where clinical trial is conducted

Argentina,  Brazil,  France,  India,  South Africa,  Spain,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability of DRV/rtv in combination with other ARVs will be summarized in terms of Mortality, all Serious Adverse Events,Adverse events leading to discontinuation and Adverse Events at least possibly related to the DRV treatment Variable, up to 7 years No
See also
  Status Clinical Trial Phase
Completed NCT01013415 - CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients Phase 1
Completed NCT01151319 - Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults Phase 1
Completed NCT01138605 - TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV Phase 2
Completed NCT01078233 - Observational Data Analysis in EuroSIDA (MK-0518-058)
Recruiting NCT02593409 - HIV PrEP Priming of Immune Effectors Phase 4
Completed NCT00557245 - Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples Phase 3
Withdrawn NCT00984152 - Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women Phase 3
Completed NCT00799058 - A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States Phase 1/Phase 2
Completed NCT01159275 - Lopinavir (LPV) Dose Reduction Phase 1/Phase 2
Completed NCT01281813 - TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV Phase 3
Completed NCT01078246 - Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
Active, not recruiting NCT03027297 - TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV Phase 3
Completed NCT01139905 - Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children Phase 2
Completed NCT01033760 - Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM) Phase 3
Completed NCT00830804 - Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults Phase 2
Completed NCT01074931 - Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China N/A